Prognostic role of Vitagnus® oral tablets in Multiple Sclerosis: A pilot study in premenopausal women

Background: Multiple Sclerosis is an autoimmune neurodegenerative disease with higher prevalence in young-aged ladies. Several studies have shown that sex hormones can influence the risk of developing or prognosis of MS. Vitex agnus-castus (VAC.) herb regulates sexual hormones and has anti-inflammatory and neuroprotective effects.Aims and objectives: This study has aimed to investigate the role of daily administration of Vitagnus oral tablet on Quality of Life (QOL) parameters and serum testosterone levels in premenopausal multiple sclerosis patients.Methods: Vitagnus oral tablets have been taken twice a day for 3 months by 30 premenopausal multiple sclerosis women with IR.IAU.PS.REC.1396.169 ethics code. Demographic and MSQOL-54 questionnaires were filled out and serum testosterone levels and EDSS were compared at the baseline and after 3 months of intervention. Mean levels of all parametric variables were compared by paired t-test and Wilcoxon test for non-parametric variables using SPSS 21 software with significance level of ≤0.05. Results: After 3 months of taking Vitagnus tablets, most of QOL variables and serum testosterone levels were significantly increased and EDSS decreased (p≤0.05) compared to baseline levels. Menstrual irregularities were regulated in all patients and most of patients experienced lower stress levels, improved vitality, normalized sexual activities and self-esteem.Conclusion: Due to impressive prognostic effects of Vitagnus tablets, it could be considered as a new integrative method with confident beneficial effects in women suffering from multiple sclerosis.

Keywords:

Vitex agnus-castus , Multiple Sclerosis , clinical symptoms , Quality of Life , testosterone serum level